H4
An anti-SARS-CoV-2 monoclonal antibody.
General information
H4 is a human anti-SARS-CoV2 monoclonal antibody. It was isolated from a memory B cell from a serum sample of a COVID-19 convalescent patient. It was selected for its affinity for Spike protein RBD. It neutralized SARS-CoV-2 in vitro. The antibody acted synergistically with B38. It reduced viral titres and reduced lung pathology in mice after a challenge (Wu et al., 2020). The antibody’s tertiary structure and interaction with Spike RBD has been described by Rapp et al. (2021). H4 can be produced in a Nicotiana benthamiana plant expression system (Shanmugaraj et al., 2020).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Monoclonal Antibodies B38 and H4 Produced in Nicotiana benthamiana Neutralize SARS-CoV-2 in vitro
Spike protein In vitro Antibody |
in vitro binding assay; Vero E6 cells; SARS-CoV-2 strain SARS-CoV-2/01/human/Jan2020/Thailand | 4.40 | The antibody experimentally produced using a plant expression system bound SARS-CoV-2 Spike RBD in vitro and neutralised SARS-CoV-2 live virus in Vero E6 cells. It was more potent than |
Nov/27/2020 |
|
A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2
Spike protein Biophysical assay Animal model In vitro Antibody Screening |
in vitro biophysical assay; crystallization; Vero cells; hACE2 mice; SARS-CoV-2 strain BetaCoV/Shenzhen/SZTH-003/2020 | 41.85 | The antibody neutralized SARS-CoV-2 with an IC50 of 0.896 μg/mL in vitro. It acted synergistically with <a href= |
Jun/12/2020 |
AI-suggested references
Clinical trials
| ID | Title | Status | Phase | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05173441 | Human COVID-19 Immunoglobulin (COVID-HIG) Therapy for COVID-19 Patients | Not yet recruiting | Phase 2 | Dec/30/2021 | Nov/30/2023 |
|
|||||
